1.564
price up icon0.90%   0.014
 
loading
Schlusskurs vom Vortag:
$1.55
Offen:
$1.64
24-Stunden-Volumen:
2,585
Relative Volume:
0.17
Marktkapitalisierung:
$54.83M
Einnahmen:
$1.88M
Nettoeinkommen (Verlust:
$-15.57M
KGV:
-3.91
EPS:
-0.4
Netto-Cashflow:
$-50.09M
1W Leistung:
+13.97%
1M Leistung:
+7.64%
6M Leistung:
-30.11%
1J Leistung:
-30.18%
1-Tages-Spanne:
Value
$1.64
$1.64
1-Wochen-Bereich:
Value
$1.31
$1.6735
52-Wochen-Spanne:
Value
$0.98
$3.625

Beyondspring Inc Stock (BYSI) Company Profile

Name
Firmenname
Beyondspring Inc
Name
Telefon
646-528-4184
Name
Adresse
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Name
Mitarbeiter
40
Name
Nächster Verdiensttermin
2024-08-05
Name
Neueste SEC-Einreichungen
Name
BYSI's Discussions on Twitter

Vergleichen Sie BYSI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BYSI
Beyondspring Inc
1.64 54.83M 1.88M -15.57M -50.09M -0.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.67 126.09B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
582.18 64.01B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
640.20 36.63B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
256.50 30.64B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
262.88 26.85B 3.81B -644.79M -669.77M -6.24

Beyondspring Inc Stock (BYSI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-12-02 Herabstufung BofA Securities Buy → Underperform
2021-12-02 Herabstufung Jefferies Buy → Hold
2021-12-01 Herabstufung H.C. Wainwright Buy → Neutral
2021-12-01 Herabstufung William Blair Outperform → Mkt Perform
2021-09-09 Eingeleitet Robert W. Baird Outperform
2021-08-04 Hochstufung H.C. Wainwright Neutral → Buy
2021-04-05 Herabstufung H.C. Wainwright Buy → Neutral
2021-01-11 Eingeleitet BofA Securities Buy
2020-12-29 Eingeleitet Evercore ISI Outperform
2020-02-07 Eingeleitet Jefferies Buy
2020-01-10 Eingeleitet Nomura Buy
2019-12-03 Eingeleitet William Blair Outperform
2019-07-10 Bestätigt H.C. Wainwright Buy
2019-04-30 Herabstufung Maxim Group Buy → Hold
2018-10-25 Bestätigt Maxim Group Buy
Alle ansehen

Beyondspring Inc Aktie (BYSI) Neueste Nachrichten

pulisher
Apr 29, 2025

SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN

Apr 29, 2025
pulisher
Apr 10, 2025

BeyondSpring (NASDAQ:BYSI) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat

Apr 10, 2025
pulisher
Apr 04, 2025

BeyondSpring stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

BeyondSpring stock hits 52-week low at $1.34 amid market challenges - Investing.com India

Apr 04, 2025
pulisher
Mar 30, 2025

BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat

Mar 30, 2025
pulisher
Mar 29, 2025

BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks

Mar 29, 2025
pulisher
Mar 28, 2025

BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com

Mar 28, 2025
pulisher
Mar 27, 2025

BeyondSpring Inc. (BYSI) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Just Released: BeyondSpring's Complete 2024 Financial Performance and Cancer Pipeline Updates - Stock Titan

Mar 27, 2025
pulisher
Mar 25, 2025

Global Febrile Neutropenia Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, And - EIN News

Mar 25, 2025
pulisher
Mar 25, 2025

In-Depth Analysis Of The Global Febrile Neutropenia Market Advancements Highlighted by Key Drivers, Trends,... - WhaTech

Mar 25, 2025
pulisher
Mar 25, 2025

BeyondSpring's PlinabulinA Pipeline In Itself? - RTTNews

Mar 25, 2025
pulisher
Mar 19, 2025

Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve

Mar 19, 2025
pulisher
Mar 09, 2025

BeyondSpring, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 04, 2025

Pliant Therapeutics stock tumbles amid IPF trial cancellation - Clinical Trials Arena

Mar 04, 2025
pulisher
Feb 25, 2025

BeyondSpring finalizes significant asset sale By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

BeyondSpring finalizes significant asset sale - Investing.com India

Feb 25, 2025
pulisher
Feb 24, 2025

BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.6%Time to Buy? - MarketBeat

Feb 24, 2025
pulisher
Feb 17, 2025

Cancer Vaccines Market on Track for Major Expansion in - One News Page

Feb 17, 2025
pulisher
Feb 12, 2025

Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online

Feb 12, 2025
pulisher
Feb 05, 2025

Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights

Feb 05, 2025
pulisher
Jan 31, 2025

BeyondSpring Inc. Enters into Preferred Share Purchase Agreement with SEED Therapeutics Inc. - Defense World

Jan 31, 2025
pulisher
Jan 29, 2025

BeyondSpring sells SEED Therapeutics shares for $35.4M - MSN

Jan 29, 2025
pulisher
Jan 28, 2025

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - The Manila Times

Jan 28, 2025
pulisher
Jan 28, 2025

BeyondSpring sells SEED Therapeutics shares for $35.4M By Investing.com - Investing.com UK

Jan 28, 2025
pulisher
Jan 28, 2025

BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire

Jan 28, 2025
pulisher
Jan 28, 2025

SEED Receives FDA Rare Pediatric Disease and Orphan Drug - GlobeNewswire

Jan 28, 2025
pulisher
Jan 28, 2025

BeyondSpring Cashes In $35M Stake as Cancer Drug Shows 89% Disease Control Rate - StockTitan

Jan 28, 2025
pulisher
Jan 26, 2025

BeyondSpring (NASDAQ:BYSI) Shares Down 1.4%Here's Why - MarketBeat

Jan 26, 2025
pulisher
Jan 15, 2025

Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve

Jan 15, 2025
pulisher
Jan 05, 2025

BeyondSpring Inc. Announces Change in Domestic Filing Status and Disclosure Channels to Disseminate Information - Defense World

Jan 05, 2025

Finanzdaten der Beyondspring Inc-Aktie (BYSI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.99
price up icon 1.91%
$71.40
price down icon 0.28%
$32.90
price up icon 0.11%
$23.21
price down icon 1.78%
$104.43
price up icon 0.23%
biotechnology ONC
$263.58
price up icon 5.77%
Kapitalisierung:     |  Volumen (24h):